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Introduction
In the current controlled ovarian hyperstimulation (COH) 
cycle management, gonadotrophin releasing hormone 
(GnRH) agonists or gonadotrophin releasing hormone antag-
onists are indispensable agents for the prevention of pre-
mature luteinization with acceptable live birth rates (1-3). 
However, supraphysiological steroid hormone levels together 
with the suppressed luteinizing hormone (LH) levels by both 
GnRH agonist and GnRH antagonist administration during 
COH cycles lead to a defect in the luteal phase, particularly in 
in vitro fertilization (IVF) cycles (3-8). Therefore, use of medi-
cation for luteal phase support (LPS) has been considered to 
be mandatory to ensure intact corpus luteum function and to 
avoid any decrease in implantation and pregnancy rates (7, 
9). There is still controversy over the best LPS agent and pro-
tocol and its dose and duration as well as the time of initiation 
and cessation (10). Intravaginal or intramuscular progester-
one application has become the routine practice to support 
luteal phase in COH cycles over the years either alone or in 
combination with estradiol (7, 11, 12). However, there is still a 
search to provide optimal luteal support for better pregnancy 
outcome rates in COH cycles. 
In recent years, the beneficial effects of single or repeated 
doses of GnRH agonist for luteal phase support were con-
sidered in different studies. GnRH agonist luteal support was 
hypothesized to support luteal phase by various mechanisms. 
Augmentation of the corpus luteum function by increasing 
LH secretion by the pituitary cells, direct stimulation of endo-
metrial local GnRH receptors, and potential direct stimulation 
effect of GnRH agonist on the embryo, which was evidenced 
by increased beta human chorionic gonadotropin (β-hCG) 
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secretion were some of the proposed potential mechanisms of 
actions (13, 14). 
The purpose of this study was to evaluate whether the addition 
of single-dose GnRH agonist to the progesterone for luteal sup-
port in IVF cycles improves the pregnancy outcome measures, 
particularly the live birth rates. 
 
Material and Methods
Study design and study population 
This study was a retrospective study conducted at Başkent 
University, Obstetrics and Gynecology Department Infertility 
and IVF Unit, from January 2006 to October 2013. Başkent 
University Institutional Review Board approved this study (proj-
ect number: KA 12/57). 
The inclusion criteria were as follows:
Couples undergoing IVF with their own gametes
Women below 40 years of age and follicle stimulating hormone 
(FSH) <10 IU
First two IVF cycles with long GnRH agonist or GnRH antagonist 
cycles with fresh embryo transfers
Couples having at least one grade 1 embryo available for transfer
Cleavage state embryo transfer [Day 3 embryo transfer after 
intracytoplasmic sperm injection (ICSI) IVF cycles with luteal 
phase support with intravaginal or intramuscular progesterone 
alone or in combination with triptorelin acetate (GnRH ago-
nist)]
Ovarian stimulation and Assisted Reproductive Techniques (ART)
In the long GnRH agonist group, ovarian down-regulation was 
initiated with either daily 1 mg leuprolide acetate (Lucrin, 
Abbott GmbH) or 0.1 mg triptorelin (Decapeptyl, Ferring GmbH) 
that was commenced on Day 21 of the preceding menstrual 
bleeding. After ovarian suppression was achieved, the dose 
was reduced by half until the day of administering hCG. If there 
were no follicle cysts beyond 2 cm and the estradiol was <50 
pg/mL, 150-300 IU gonadotropin stimulation with recombi-
nant FSH (rFSH) (Puregon, MSD, the Netherlands) and rFSH 
(Gonal F, Merck Serono GmbH, Greece) or human menopausal 
gonadotropin (hMG) (Menogon, Ferring GmbH, Germany) was 
initiated with estradiol monitoring starting on the fifth day of 
stimulation. Ultrasound and blood estradiol and progesterone 
levels were continuously monitored until the day of ovulation 
induction with hCG, providing the criteria with three or more 
follicles that were of a diameter >17 mm.
In the GnRH antagonist group, gonadotropin stimulation with 
150-300 IU of gonadotropins rFSH (Puregon, MSD GmbH), 
(Gonal F, Merck Serono GmbH) or hMG (Menogon, Ferring 
GmbH) was initiated on Day 3 of menstruation. Fixed GnRH 
antagonist protocol was performed by daily subcutaneously 
administering 0.25 mg ganirelix (Orgalutran, Organon, the 
Netherlands), which was commenced on the sixth day of stim-
ulation. Blood progesterone and estradiol and progesterone lev-
els were monitored until the day of ovulation induction by hCG. 
The criteria for ovulation induction were similar to the agonist 
stimulation cycles with three or more follicles >17 mm. Oocyte 
retrieval was performed 35-36 h after administering 10,000 IU 
hCG (Pregnyl, Organon Turkey) or 250 mg recombinant hCG 
(rhCG) (Ovitrelle, Merck Serono, Italy) under transvaginal 
ultrasonography guidance. The 17-gauge single-lumen needles 
were used for oocyte retrieval under sedation with propofol 
(propofol 1% Fresenius KabiR). Routine ICSI was performed 
for every case after 2-2.5 h of incubation. Embryos were trans-
ferred at the cleavage stage, three days after ICSI. 
Luteal phase support
Progesterone was the routine luteal support agent, and patients 
had luteal support either in the form of 90 mg intravaginal 
progesterone (Crinone 8% gel, Merck Serono GmbH) or 50 
mg intramuscular progesterone (Progynex ampule, FARMACO 
GmbH). Progesterone support was commenced after the day 
of oocyte pick-up and continued until 10 completed weeks of 
pregnancy. In the GnRH agonist luteal support group, patients 
also received an additional single dose of 0.1 mg GnRH agonist 
namely, triptorelin (Decapeptyl Ferring GmbH) three days after 
the transfer (six days after ICSI). Pregnancy was defined as posi-
tive for hCG on detection of above 10 IU/mL, 12 days after the 
embryo transfer. Implantation rate was individually calculated 
for each woman as the number of gestational sac divided by the 
number of transferred embryos multiplied by 100. Presence of 
at least one gestational sac was defined as clinical pregnancy 
with fetal cardiac activity that was detectable by transvaginal 
ultrasound scans. Live birth rate was the birth of a viable fetus 
beyond 24 weeks of gestation. 
Statistical analysis
Data, which were shown to evenly distribute, were expressed 
as means±SD. The baseline differences between the two 
groups were analyzed by independent t-test or one-way ANOVA 
test. The parameters with uneven distribution were expressed 
as median and minimum maximum values. The differences 
between the two groups were evaluated by Mann-Whitney U 
test. In contingency tables, the χ2 test or the two-sided Fisher’s 
exact test was performed. A value of p<0.05 was considered 
statistically significant. SPSS 20.0 for Windows was used for 
data analysis version 20.0 (SPSS Inc. IBM, Chicago, IL, USA).
Results
Among 9470 IVF cycles, a total of 2739 IVF cycles, which met 
the inclusion criteria, were included in the analysis (Figure 
1). Baseline characteristics of the patients were presented in 
Table 1. The mean age of patients, body mass index (BMI), and 
Day 3 FSH levels and antral follicle count were similar between 
the groups. Cycle characteristics were listed in Table 2. Days 
of stimulation, retrieved oocytes and metaphase II oocytes 
numbers, estradiol levels, and endometrial thickness at the day 
of ovulation trigger were found to be similar. Grade 1 embryo 
number and the number of transferred embryos were found to be 
significantly high in progesterone only luteal support group in long 
agonist stimulation arm, and on the contrary, these values were 
found to be significantly low in the antagonist stimulation arm. 
As we investigate the main outcome measures, live birth rates 
were not found to be statistically different in GnRH agonist 
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plus progesterone (Group A) and progesterone only group 
(Group B) in both the long agonist and antagonist stimulation 
arms (40.8%/41.2% and 32.8%/34.4%, respectively). Moreover, 
pregnancy, implantation, and miscarriage rates were found to 
be similar between the groups (Table 3). However, because 
the number of embryos transferred between groups was 
different, we stratified patients according to the number of 
embryos transferred. Live birth rates according to the number 
of transferred embryo were similar between the groups (Table 
4). In contrast, stratification of live birth rates according to the 
number of transferred Grade I embryo (one, two, or three or 
more grade I embryo transfer) revealed similar results with no 
significant difference between the treatment groups (Table 5). 
Regression analysis demonstrated that age, antral follicle count, 
the number of metaphase II oocyte, the number of grade I 
embryo, and the transferred embryo significantly affected live 
birth rates. Luteal GnRH agonist addition showed no effect on 
regression analysis (p=0.48). 
Discussion
The administration of GnRH agonist in the luteal phase was 
initially studied as a means of contraception with unsatisfactory 
results (15). It was observed that unintentional or accidental 
GnRH agonist administration in the luteal phase of IVF treat-
ment cycles with pregnancies did not compromise the continu-
ation of pregnancy but was observed to support implantation 
in initial reports (16-19). Although well-defined mechanisms 
by which GnRH agonist addition improves luteal support are 
lacking, presumptive effect at multiple levels were proposed. 
Direct release of LH by gonadotrophs was tested by Pirard 
et al. (20) and Tesarik et al. (14). Both Tesarik et al. (14) and 
Pirard et al. (20) found increased estradiol and progesterone 
levels during the luteal phase of GnRH agonist added cycles; 
however, the source and mechanisms of this increase were 
unclear. Furthermore, Tesarik et al. (21) reported increased 
hCG secretion in pregnancies with GnRH agonist luteal phase 
support. Authors also hypothesized a direct beneficial effect on 
implanting embryo (21), and increased levels of hCG in GnRH 
agonist luteal phase support pregnancies were observed (14). 
Moreover, authors suggested a direct stimulatory effect via 
GnRH receptors on the corpus luteum function (14). 
Tesarik et al. (21) reported a pilot study in donation cycles, and 
Pirard et al. (13) in intrauterine insemination cycles investigated 
the role of GnRH agonist as a luteal support agent. The same 
authors Tesarik et al. (14) reported a randomized study in both 
the agonist and antagonist stimulated IVF-ICSI cycles with the 
addition of 0.1 mg triptorelin to luteal support with beneficial 
Figure 1. Flowchart of cycle distribution between groups
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effects on pregnancy outcomes. Pirard et al. (20) studied differ-
ent doses of intranasal buserelin in intrauterine insemination 
and IVF cycles (13, 20). Both of Pirard et al. (13, 20) studies 
were pilot studies with very small number of patients (24 and 
23 patients in each); therefore, the pregnancy outcomes of the 
effect of GnRH addition to LPS agents were not possible to gen-
eralize. In the year 2009, Isik et al. (22) reported a study in which 
patients were blindly randomized to the addition of single-dose 
0.5 mg leuprolide acetate or hCG plus progesterone groups 
(22). Implantation rate and live birth rates were reported to be 
significantly improved by GnRH agonist addition (26.5% vs. 9.3% 
and 35.1% vs. 16.3%, respectively). 
There are a considerable number of studies reporting against 
the improvement of pregnancy outcomes with GnRH analog 
addition to luteal phase support. One of the largest reported 
randomized trials with placebo control was published by Ata 
et al. (6) that included 570 patients in long agonist IVF stimula-
tion cycles. The effect of the addition of a single dose of 0.1 mg 
triptorellin injection was not found to be superior over standard 
uniform intravaginal progesterone luteal phase support treat-
ment (6). In the year 2010, the same authors investigated the 
role of GnRH agonist addition in the antagonist stimulated IVF 
cycles with the same study design demonstrating no beneficial 
effects of GnRH agonist addition on pregnancy outcomes (23). 
Isikoglu et al. (24) investigated the role of luteal GnRH analog in 
a different manner by extension of GnRHa administration until 
12 days after embryo transfer in long agonist IVF-ICSI cycles. 
Authors did not report any significant improvement of implanta-
tion, clinical pregnancy, and live birth rates after randomization 
of 180 patients (24). Most recently, Yıldız et al. (25) in their ran-
domized study failed to demonstrate significant improvement 
of pregnancy outcomes by single or double dose of GnRH ago-
nist addition to progesterone and estradiol luteal support (25). 
There are two meta-analyses focusing on GnRH agonist addi-
tion to LPS (26, 27). Oliveira et al. (26) included five and Kyrou 
et al. (27) included six randomized studies, four of which were 
common to both meta-analyses (Tesarik 2006, Ata 2008, Isik 
2009, Razieh 2009). While Oliveira et al. (26) concluded that 
GnRH agonist addition increased implantation rates, clinical 
pregnancy rates were found to be increased only in antagonist 
cycles. In the more recent meta-analysis by Kyrou et al. (27), 
LPS with GnRH agonist was shown to significantly increase 
Table 3. Comparison of pregnancy outcome measures
    p
  Group A Group B value
Pregnancy  Long agonist 758 (66.0) 343 (61.5) 0.68
rate, n (%) Antagonist 377 (53.8) 179 (54.1) 0.92
Implantation Long agonist 33 (0-100) 33 (0-100) 0.17
rate, (%) Antagonist 33 (0-100) 33 (0-100) 0.45
Miscarriage  Long agonist 193 (16.8) 61 (10.9) 0.001
rate, n (%) Antagonist 85 (12.1) 48 (14.5) 0.28
Multiple pregnancy Long agonist 279 (24.3) 137 (24.6) 0.90
rate, n (%) Antagonist 84 (12.0) 23 (6.9) 0.01
Live birth  Long agonist 469 (40.8) 230 (41.2) 0.87
rate, n (%) Antagonist 230 (32.8) 114 (34.4) 0.60
Group A: GnRH agonist+progesterone  luteal support, Group B: Progesterone only 
luteal support.
Values=mean±2SD or Median (minimum-maximum).
Table 1. Patients’ characteristics of the study group
    P 
  Group A Group B value
Age L agonist 30.72±4.47 30.42±4.51 0.19
 Antagonist 31.04±4.69 31.00±4.67 0.89
BMI L agonist 25.34±4.18 25.46±3.92 0.79
 Antagonist 24.89±4.21 25.01±4.27 0.23
Duration of  L agonist 6.0 (0.6–22) 7.0 (1–22) 0.01
infertility (years) Antagonist 5.0 (1–26) 4.5 (1–20) 0.02
Antral follicle L agonist 6.13±2.08 5.98±2.22 0.24
count Antagonist 5.06±2.27 5.14±2.28 0.14
Basal FSH L agonist 5.89±1.79 5.94±1.99 0.62
 Antagonist 5.97±1.85 5.83±1.79 0.54
Group A: GnRH agonist+progesterone luteal support, Group B: Progesterone only 
luteal support.
Values=mean±2SD or Median (minimum–maximum).
BMI: body mass index; FSH: follicle stimulating hormone 
Table 2. Cycle Characteristics of the study group 
    p 
  Group A Group B value
Days of  Long agonist 9.33±1.71 9.32±1.63 0.96
stimulation Antagonist 8.73±2.02 8.67±2.10 0.64
Total dose of  Long agonist 2025  2250 0.001 
gonadotropins  (300–7200) (725–7500) 
 Antagonist 2062  2025 0.02 
  (225–6800)  (475–4650) 
Retrieved  Long agonist 14 (1–49) 14 (2–38) 0.90
oocyte per  Antagonist 10 (1–60) 11(1–39) 0.72 
cycle 
Metaphase II  Long agonist 11(1–45) 12 (1–35) 0.58
oocyte number Antagonist 9 (1–56) 9 (1–37) 0.80
Estradiol on  Long agonist 2223±1120 2162±1247 0.31
day of hCG Antagonist 1580±1044 1547±998 0.63
Grade I embryo  Long agonist 2 (1–5) 2 (1–4) 0.003
number Antagonist 1 (1–5) 1 (1–5) 0.001
Number of  Long agonist 3 (1–6) 3 (1–5) 0.001
transferred  Antagonist 2 (1–5) 1 (1–5) 0.001
embryo 
Endometrial  Long agonist 12.01±2.14 11.17±2.51 0.36
thickness on  Antagonist 11.72±2.29 10.64±2.15 0.39
day of hCG 
Group A: GnRH agonist+progesterone luteal support, Group B: Progesterone only 
luteal support. 
Values=mean±2SD or Median (minimum–maximum).
hCG: human chorionic gonadotrophin 
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live birth rate (27). However, heterogeneity of data were 
prominent because of different agents used for luteal phase 
support, including various combinations of progesterone, 
estradiol, and hCG, among the studies [Tesarik et al. (14): vagi-
nal micronized progesterone+r-hCG (single dose)+estradiol 
valerate; Ata et al. (6): Vaginal progesterone gel; Isik et al. (22): 
vaginal micronized progesterone+single-dose hCG; Isikoglu et 
al. (24): intramus cular progesterone; Razieh et al. (29): intra-
vaginal progester one; Fuji et al. (30): dydrogesterone+hCG) 
(6, 14, 22, 28-30). Therefore, luteal phase support regimens 
were not uniform. 
Furthermore, in the meta-analysis and in different random-
ized studies, different doses, types and application route, and 
repeated doses of GnRHa were used, which would most prob-
ably cause considerable amount of heterogeneity of data and 
concerns of data interpretation [Fuji et al. (30): Buserelin 14 
days after egg retrieval; Tesarik et al. (14): single-dose triptore-
lin; Ata et al. (6): 0.1 mg single-dose triptorelin; Isik et al. (22): 
single-dose 0.5 mg leuprolid; Isikoglu et al. (24): GnRHa 14 days 
after egg retrieval; Razieh et al. (29); single-dose 0.1 mg triptore-
lin; Yıldız et al. (25): single or double doses of 1 mg leuprolid].  
All the aforementioned heterogeneities preclude drawing firm 
conclusions for the beneficial effects of GnRH agonist on 
reproductive outcome. Although our data was retrospective, 
uniform dose and route of administration of GnRH agonist and 
uniform luteal support combination with progesterone made 
comparison of the groups more reliable. Because the number 
of transferred embryos and Grade I embryo numbers were dif-
ferent between the groups, we performed subgroup analysis 
(Table 4, 5). By these analyses, we aimed to alleviate the con-
founding heterogeneity between the groups with respect to 
the number of both transferred embryos and Grade I embryos. 
After stratification of cycles, we ended up with the same con-
clusion of absence of beneficial effects of luteal GnRH agonist 
addition to progesterone in IVF cycles with respect to preg-
nancy outcome measures (Table 4, 5). 
Another remarkable result was the significantly increased mul-
tiple pregnancy rates in antagonist cycles with GnRH agonist 
addition. However, this result was not observed in long agonist 
cycles with GnRH agonist arm in our study (Table 3). Increase in 
multiple pregnancies was observed in the studies of Tesarik et 
al. (14), Isik et al. (22), Yıldız et al. (25). It can be speculated that 
GnRH agonist addition may increase multiple pregnancy rates 
either by direct effect on embryo implantation via GnRH recep-
tors present on the endometrium or by the receptors present on 
the embryo. However, any effect of this kind awaits verification 
in further studies with selective single embryo transfer cycles. 
After initial clinical randomized trials with beneficial effects, 
we used GnRH agonist as a luteal adjunct in long agonist and 
antagonist stimulation IVF cycles relatively liberally in our IVF 
clinic. Absence of anticipated increase in live birth rates led us 
to cease routine GnRH agonist addition to progesterone in our 
clinic. Therefore, we reached the highest numbers of GnRH 
agonist administered cycles. Although retrospective in nature, 
this study constitutes the largest study on the effect of GnRH 
agonist addition to luteal support in IVF cycles. Predetermined 
fixed dose of GnRH agonist administration and standard luteal 
phase support with progesterone strengthen our data for more 
uniform analysis. However, there are limitations to our analysis: 
retrospective nature and uncontrollable patient and cycle char-
acteristics preclude drawing firm conclusions. Although we 
tried to eliminate many confounding variables with strict inclu-
sion criteria, there are still some other factors such as longevity 
of study with different culture mediums and different infertility 
reasons that may affect pregnancy outcome measures. 
Although there are considerable studies on literature, beneficial 
effects on pregnancy outcome measures were highly blurred 
by the lack of uniform administration of GnRH agonist in regard 
to effective dose, administration period, and absence of ideal 
combination with which GnRH agonist combines with other 
luteal phase supporting agent or agents (i.e., progesterone, 
estradiol, hCG). 
In conclusion, our study failed to demonstrate any benefit of 
addition of single 0.1 mg dose of luteal GnRH analog (triptore-
lin) to the routine luteal phase support with progesterone in 
IVF cycles on live birth rates. The mechanisms of actions and 
the ideal dose, administration route, and time interval of GnRH 
agonist administration in the luteal phase support remain large-
ly undetermined. Presumptive beneficial effect, if any, may only 
be uncovered after carefully designed preclinical studies and 
well-designed randomized clinical studies with different dose 
regimens and administration routes. In the light of current lit-
erature and our findings, routine administration of single-dose 
GnRH agonist as a beneficial luteal phase adjunct in IVF cycles 
Table 4. Live Birth Rates according to the number of trans-
ferred embryo
    p
Number of transferred embryo Group A Group B value
1 embryo, n (%) Long agonist 56 (31.6) 18 (28.1) 0.60
 Antagonist 92 (33.6) 60 (32.1) 0.73
2 embryos, n (%) Long agonist 63 (36.2) 18 (31.0) 0.47
 Antagonist 67 (30.2) 46 (36.5) 0.22
3 or more  Long agonist 350 (43.9) 194 (44.5) 0.84
embryos, n (%) Antagonist 71 (34.6) 8 (44.4) 0.40
Group A: GnRH agonist+progesterone luteal support, Group B: Progesterone only 
luteal support.
Table 5. Live Birth Rates according to the transfer of num-
ber of grade 1 embryo
    p
Number of grade I embryo Group A Group B value
1 Grade I embryo, Long agonist 208 (37.1) 86 (35.8) 0.75
n (%) Antagonist 162 (32.0) 88 (32.4) 0.94
2 Grade I embryos, Long agonist 141 (41.2) 70 (44.9) 0.49
n (%) Antagonist 49 (35.3) 20 (39.2) 0.61
3 or more grade I  Long agonist 120 (48.8) 74 (45.7) 0.54
embryos, n (%) Antagonist 19 (44.7) 6 (56.8) 0.16
Group A: GnRH agonist+progesterone luteal support, Group B: Progesterone only 
luteal support.
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cannot be recommended until after future randomized studies 
prove the beneficial effects. 
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